Vista Pharmaceuticals Reports Widened Q3FY26 Loss on Higher Expenses
Vista Pharmaceuticals Ltd · Financial Result · 13 Feb 2026, 8:53 pm
Vista Pharmaceuticals Reports Widened Q3FY26 Loss on Higher Expenses Vista Pharmaceuticals reported a widened net loss of ₹231.94 lakh for Q3FY26 ended 31 Dec'25, compared to a loss of ₹132.23 lakh YoY. Revenue from operations declined 5.4% YoY to ₹241.82 lakh. The loss before tax increased to ₹328.04 lakh from ₹180.44 lakh YoY, driven by higher material and other expenses. The company also recognized an Expected Credit Loss provision of ₹205.43 lakh against trade receivables. Basic EPS for the quarter stood at ₹(0.41), deteriorating from ₹(0.07) in the prior-year period.
Original exchange filing (PDF)
More announcements from Vista Pharmaceuticals Ltd
- Resignation of Company Secretary & Compliance Officer · 12 Sept 2026
- Results for the quarter ended 30.06.2026 · 14 Aug 2026
- Results for the quarter ended 30.06.2026 · 14 Aug 2026
- Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. Unaudited financial .... · 14 Aug 2026
- Board meeting outcome · 29 May 2026
- Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve 1. Audited financial .... · 29 May 2026
- <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> .... · 29 Apr 2026
- Un audited Financial Results for the quarter ended 31.12.2025 · 13 Feb 2026
